19:11 , May 19, 2017 |  BC Week In Review  |  Company News

EC opens investigation into Aspen's EU pricing practices

The European Commission began a formal investigation of Aspen Pharmacare Holdings Ltd. (JSE:APN) amid concerns that the company breached EU antitrust rules by excessively raising the prices of five off-patent cancer medicines: chlorambucil, melphalan, mercaptopurine,...
21:52 , Feb 9, 2017 |  BC Week In Review  |  Clinical News

LentiGlobin BB305 gene therapy: Ph I HGB-206 amended

bluebird amended the open-label, U.S. Phase I HGB-206 trial evaluating IV LentiGlobin BB305 to increase production of therapeutic anti-sickling hemoglobin and increase enrollment to up to 29 patients from up to 8. The changes include...
07:00 , Sep 28, 2015 |  BioCentury  |  Emerging Company Profile

Microparticle man

RxMP Therapeutics LLC is developing microparticles harvested from red blood cells to mitigate excessive bleeding during surgery or trauma by promoting clotting at sites of bleeding without instigating unwanted coagulation. Available hemostatics used for acute...
07:00 , Jun 23, 2014 |  BioCentury  |  Product Development

Battling beta T

Data presented at the European Hematology Association meeting this month suggest both bluebird bio Inc. and Acceleron Pharma Inc. could have the first two disease-modifying treatments for beta thalassemia. While bluebird's gene therapy approach could...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

Busulipo regulatory update

Pharmalink said FDA granted Orphan Drug designation for Busulipo, a liposome formulation of the generic chemotherapeutic busulfan, as a conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation (HSCT). The company...
00:17 , Oct 5, 2013 |  BC Extra  |  Financial News

Pharmalink raises $15 million in series C

Pharmalink AB (Stockholm, Sweden) raised SEK96 million ($15 million) in a series C round co-led by new investor Investinor and existing investor Industrifonden. The company's founders, who are existing investors, also participated. Next year, Pharmalink...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Company News

Astex Pharmaceuticals, Otsuka Pharmaceutical deal

Otsuka will acquire Astex for $8.50 per share in cash, or about $866 million. The price is a 27% premium to Astex's close of $6.68 on Sept. 3, before rumors surfaced that Otsuka was acquiring...
23:48 , Sep 5, 2013 |  BC Extra  |  Top Story

Otsuka acquiring Astex

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) will acquire Astex Pharmaceuticals Inc. (NASDAQ:ASTX) for $8.50 per share in cash, or about $866 million. The price is a 27% premium to Astex's close of $6.68 on Tuesday,...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

Cal-1: Phase I/II started

Calimmune began an open-label, U.S. Phase I/II to evaluate Cal-1 with and without conditioning agent Busulfex busulfan in 12 HIV-positive patients previously on highly active antiretroviral therapy (HAART). California Institute for Regenerative Medicine (San...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Company News

Kyowa Hakko Kirin, Otsuka Pharmaceutical deal

The companies terminated a deal under which Kyowa acquired development and commercialization rights to Busulfex busulfan from Otsuka. As part of the termination, which is effective March 31, 2013, Kyowa will receive a payment...